SCHEMBL4201773

SCHEMBL4201773

CC(=O)Nc1nc(C)c(-c2cc(S(=O)(=O)O)ccn2)s1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 13/20 0.55
PIK3CA P42336 9/20 0.55
PIK3CD O00329 8/20 0.55
PIK3CB P42338 8/20 0.55
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 1/20 0.48
MITF O75030 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4214047 0.82 PIK3CG (0.59) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL1890662 0.80 PIK3CG (0.59) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL4204281 0.80 PIK3CG (0.53) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL927884 0.79 PIK3CD (0.60) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL1889193 0.77 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL1890923 0.76 PIK3CG (0.60) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL4200870 0.76 PIK3CG (0.54) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL4208518 0.75 PIK3CG (0.59) PIK3CGPIK3CAPIK3CDPIK3CB
SCHEMBL4213933 0.75 PIK3CG (0.70) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL1887212 0.74 PIK3CG (0.55) PIK3CGPIK3CAPIK3CDPIK3CBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029997-A1 Thiazole Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2009-01-29 US claimed
EP-1979346-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2008-10-15 EP claimed
WO-2007082956-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2007-07-26 WO claimed
US-20090029997-A1 Thiazole Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2009-01-29 US disclosed
EP-1979346-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2008-10-15 EP disclosed
WO-2007082956-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029997-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC PIK3CG 2526/4885PIK3CA 1647/4885PIK3CD 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.